Background: Statistical models based on item response theory were used to examine (a) the performance of individual Positive and Negative Syndrome Scale (PANSS) items and their options ...

RVPH RECOVER Vocal Biomarker Data On September 4, 2024, Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) held a key ...

The new safety data from Phase III and I trials showing an absence of postinjection syndrome, a rare and serious side effect ...

As the FDA prepares to render a verdict on BMS’ closely watched schizophrenia drug, BioSpace takes a closer look at the ...

Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (TEVA), announced new positive efficacy, safety and ...

There is no single test to diagnose schizophrenia. Healthcare professionals may use a variety of tests to rule out other ...

Newron today announces its financial and operational results for the half year ended June 30, 2024, and provides an update on ...

Brief Psychiatric Rating Scale (BPRS) Diagnostic classification and rating scales used in psychiatry)± Positive and Negative Syndrome Scale (PANSS) Scale for the Assessment of Positive Symptoms (SAPS) ...

Neurocrine Biosciences’ schizophrenia program pivot has failed. | Neurocrine Biosciences’ schizophrenia program pivot has ...

The FDA is poised to issue a decision soon on KarXT, a potential first-in-class antipsychotic for schizophrenia. What should ...

Explore the latest strides in schizophrenia treatment development as 2024 heralds a pivotal year, with promising collaborations and trials.